Pharma BD Deal Intelligence
A rare private-equity win in pharma generics: Bain Capital and Cinven's $6.1B take-private of STADA more than doubled EBITDA and is now being sold on to CapVest at a premium. Though the touted 2023 Russia "exit" proved cosmetic—Putin seized the retained Nizhpharm asset in 2025 anyway.
A rare PE win in pharma generics — STADA roughly doubled EBITDA and is being sold on to CapVest at a premium — but the Russia "exit" was cosmetic and got seized by Putin anyway in 2025.
Full analysis, sources & comparables →Fierce Pharma noted Bain and Cinven were forced to raise their bid twice under pressure from Elliott Management and Active Ownership, suggesting the buyers…
STADA reported FY2017 generics segment sales up 6% to €1,361.7M and group sales of ~€2.3B; management guided continued mid-single-digit growth under new PE…
Looking back, Bain and Cinven 'transformed STADA from a traditional German generics business into a leading, diversified global healthcare platform with…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Bain Capital and Cinven (Nidda Healthcare Holding AG) successfully completed a renewed voluntary public takeover of STADA at EUR 66.25/share (EUR 65.53 + EUR 0.72 dividend), valuing the German generics/biosimilars/branded OTC company at approximately EUR 5.3B (~$6.1B). 63.85% of shares tendered. The PE owners later transformed STADA into a global generics/specialty platform.
A rare PE win in pharma generics — STADA roughly doubled EBITDA and is being sold on to CapVest at a premium — but the Russia "exit" was cosmetic and got seized by Putin anyway in 2025.
Assessment window: 5yr post-close.
$231.0B Global generics market ~$231B in 2017 (US 42% share); EU biologic drug market ~€203B in 2017
Generics and biosimilars provide lower-cost equivalents of off-patent branded drugs across virtually every therapeutic area (cardiovascular, CNS, oncology, anti-infectives). STADA's portfolio additionally includes branded OTC consumer health products (e.g., Grippostad, Ladival) and specialty/biosimilar offerings, addressing chronic disease management, self-care, and health-system cost containment in Europe and emerging markets.
STADA at deal time was the #4-5 European generics player behind Teva, Sandoz (Novartis), Mylan (later Viatris), and Krka, with strong franchises in Germany, Italy, Russia/CIS, and the Balkans, and a growing biosimilars footprint via partnerships (e.g., with Alvotech and Xbrane on biosimilars to Humira and Lucentis). The European generics market in 2017 was characterized by accelerating tender pressure in Germany, patent-cliff opportunities in biologics (Remicade, Humira, Enbrel), and strategic consolidation. Bain and Cinven's thesis (Bain Capital release, https://www.baincapital.com/news/bain-capital-private-equity-and-cinven-partners-announce-intention-launch-voluntary-public) was to take STADA private to fund a transformation from a traditional German generics manufacturer into a diversified specialty/biosimilar/consumer-health platform — a thesis they ultimately delivered, growing STADA from ~€2.3B revenue in 2017 to >€4B by 2024 with 9% CAGR (BioPharma Dive, https://www.biopharmadive.com/news/stada-takeover-bain-cinven-activist-investor/440219/). Activist investor Elliott Management forced two tender-offer increases (final offer €66.25/share including dividend), validating the strategic value but compressing PE returns.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bain Capital Private Equity / Cinven Partners (Nidda Healthcare Holding AG) / STADA Arzneimittel (this deal) | 2017 | $6.1B | 82 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
← Browse all deals · How we score deals
More: 2017 deals · Other deals